| Assessment Status | Rapid Review Complete |
| HTA ID | 20044 |
| Drug | Nusinersen |
| Brand | Spinraza® |
| Indication | For the treatment of 5q spinal muscular atrophy (SMA) in adults patients (>18 years). |
| Assessment Process | |
| Rapid review commissioned | 28/09/2020 |
| Rapid review completed | 29/10/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical and cost-effectiveness compared to the current standard of care. |